ESSA Pharma Debt To Equity vs. Current Ratio
| EPIX Stock | USD 1.83 0.07 3.98% |
Debt To Equity | First Reported 2010-12-31 | Previous Quarter 0.0679 | Current Value 0.0713 | Quarterly Volatility 1.05095587 |
For ESSA Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ESSA Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ESSA Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ESSA Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ESSA Pharma over time as well as its relative position and ranking within its peers.
ESSA |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ESSA Pharma. If investors know ESSA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ESSA Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.62) | Return On Assets (0.15) | Return On Equity (0.20) |
The market value of ESSA Pharma is measured differently than its book value, which is the value of ESSA that is recorded on the company's balance sheet. Investors also form their own opinion of ESSA Pharma's value that differs from its market value or its book value, called intrinsic value, which is ESSA Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ESSA Pharma's market value can be influenced by many factors that don't directly affect ESSA Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ESSA Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ESSA Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ESSA Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ESSA Pharma Current Ratio vs. Debt To Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ESSA Pharma's current stock value. Our valuation model uses many indicators to compare ESSA Pharma value to that of its competitors to determine the firm's financial worth. ESSA Pharma is rated below average in debt to equity category among its peers. It is one of the top stocks in current ratio category among its peers fabricating about 43,430 of Current Ratio per Debt To Equity. At this time, ESSA Pharma's Debt To Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ESSA Pharma's earnings, one of the primary drivers of an investment's value.ESSA Current Ratio vs. Debt To Equity
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
ESSA Pharma |
| = | 0 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
ESSA Pharma |
| = | 43.43 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
ESSA Current Ratio Comparison
ESSA Pharma is currently under evaluation in current ratio category among its peers.
ESSA Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ESSA Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ESSA Pharma will eventually generate negative long term returns. The profitability progress is the general direction of ESSA Pharma's change in net profit over the period of time. It can combine multiple indicators of ESSA Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -1.9 M | -1.8 M | |
| Operating Income | -28.9 M | -27.5 M | |
| Net Loss | -23.9 M | -25.1 M | |
| Income Before Tax | -23.9 M | -25.1 M | |
| Total Other Income Expense Net | 6.4 M | 6.7 M | |
| Net Loss | -31.6 M | -30 M | |
| Net Loss | -23.9 M | -25.1 M | |
| Income Tax Expense | 1.4 K | 1.4 K | |
| Interest Income | 6.4 M | 6.7 M | |
| Net Interest Income | 6.4 M | 6.7 M | |
| Change To Netincome | 8.1 M | 8.5 M | |
| Net Loss | (2.65) | (2.78) | |
| Income Quality | 0.94 | 1.28 | |
| Net Income Per E B T | 1.15 | 1.10 |
ESSA Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ESSA Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ESSA Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ESSA Pharma's important profitability drivers and their relationship over time.
Use ESSA Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ESSA Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ESSA Pharma will appreciate offsetting losses from the drop in the long position's value.ESSA Pharma Pair Trading
ESSA Pharma Pair Trading Analysis
The ability to find closely correlated positions to ESSA Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ESSA Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ESSA Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ESSA Pharma to buy it.
The correlation of ESSA Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ESSA Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ESSA Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ESSA Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ESSA Pharma position
In addition to having ESSA Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Gold ETFs Thematic Idea Now
Gold ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Gold ETFs theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gold ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.